Coronavirus and Repo – Institutional Crypto – Buy-side Collateral Responsibility

Join Our Email List

View this email in your browser

This Week's Top Stories

Finadium updates: new mutual fund seclending data, SOFR Averages, events and review of market predictions

March 5 2020

It’s been a very active Q1 2020 at Finadium, both in our product development and the complex changes in market dynamics that the coronavirus and Brexit have introduced. Here’s a product update, along with a review of some predictions we’ve made in the last couple of years.

Taming the “Wild East”: what’s happening for institutional crypto

March 4 2020

Some interesting reports about the way trading strategies are shaping in the crypto world caught our attention recently. We interview the digital assets derivatives exchange behind the reports, and speak with expert Demelza Hays about the implications for emerging market structures as increasingly sophisticated venues proliferate.

Coronavirus: US funding news update

March 3 2020

An update on what the Fed and financial authorities are doing, and which commentators are getting the story right.

Global force majeure creep into the collateral world (Premium)

March 3 2020

China’s Council for the Promotion of International Trade (CCPIT) has issued a record number of force majeure certificates, now at 1,615, covering $15.7 billion in transactions. An expansion of the coronavirus or merely fears about the virus, and more force majeure decisions around the world, would mean a new set of demand requirements for collateral markets.

Have we hit a tipping point of buy-side firms taking responsibility for their own collateral? (Premium)

March 3 2020

Calls for the buy-side to take greater responsibility for their collateral activities have been heard for years in the securities finance industry, including in this publication. The argument was that buy-side firms were leaving money and opportunity on the table by allowing dealers to decide what collateral they received in repo or securities lending, or allowing a dealer to decide what collateral to take for OTC derivatives transactions. This status quo was unlikely to hold, and we are now seeing the outcome of new thinking about business models.